May 21, 2018 / 9:30 PM / 7 months ago

FTC judge rejects agency's challenge to Endo-Impax "pay for delay" deal

A patent litigation settlement that delayed by three years the introduction of a generic painkiller did not violate consumer protection laws, a U.S. Federal Trade Commission judge ruled in a decision made public on Friday.

FTC chief administrative law judge D. Michael Chappell dismissed a complaint filed by the agency against generic drug maker Impax Laboratories LLC over its 2010 deal to postpone a generic version of Endo International Plc’s Opana ER until 2013 was anticompetitive.

To read the full story on WestlawNext Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below